PT-141 vs KPV
Side-by-side comparison of PT-141, KPV — mechanism, dosing, half-life, side effects, and research status.
| Attribute | PT-141 PT-141 (Bremelanotide) Recovery | KPV KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Melanocortin Receptor Agonist | Alpha-MSH C-terminal Tripeptide |
| Amino acids | 7 | 3 |
| Molecular weight | 1,025.2 Da | 355.4 Da |
| Half-life | ~2.7 hours | Short (hours) |
| Route(s) | Subcutaneous auto-injector | Subcutaneous, Oral (GI conditions), Topical |
| Mechanism & Research | ||
| Primary mechanism | PT-141 activates melanocortin receptors in the central nervous system — particularly MC3R and MC4R in the hypothalamus and limbic regions. Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally through va… | KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives… |
| Research status | FDA Approved (Vyleesi) | Research Compound |
| Evidence summary | PT-141 (Bremelanotide) was FDA-approved in 2019 based on two Phase 3 trials in premenopausal women with HSDD. Research in men demonstrates pro-erectile effects and is ongoing. | KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery. |
| Protocol & Dosing | ||
| Typical dose | 1.75 mg (FDA-approved dose) | 500 mcg–2 mg/day (SC); variable oral dosing |
| Frequency | As needed (max 1x per 24 hours) | Once or twice daily |
| Duration | As needed | 4–8 weeks |
| Timing | 45 minutes before anticipated sexual activity | Any time; pre-meals for GI applications |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Not Prohibited |
| Deeper reading | ||
| Related peptides | KPV, Semax | BPC-157, LL-37, TB-500 |
| Full profile | Read full PT-141 profile → | Read full KPV profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.